The revolution of the Compression Therapy Market: an easy-to-wear and comfortable compression stocking based on Electro-Active Polymers technology.

Projektinformationen

ComFyt

ID Finanzhilfevereinbarung: 775547

DOI 10.3030/775547

Abgeschlossenes Projekt

EK-Unterschriftsdatum 24 Mai 2017

Startdatum 1 Juni 2017

Enddatum 30 September 2017

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

ELASTIMED LTD
Israel

Ziel

ComFyt is a novel compression therapy stocking employing a proprietary material which eliminates the discomfort and the difficulties of traditional compression stockings. ElastiMed has identified the potential of the technology in the method of manufacturing and processing Electro-Active Polymers (EAP). The material is a soft plastic, constructed flat, with large deformation and linear activation being a unique solution, optimal for wearable devices. These actuators are able to mimic the rhythmic natural calf muscle contractions, leading to the optimal blood circulation, representing a breakthrough in the Compression Therapy.
Compression Therapy is based on a mechanical principle of applying a constant or intermittent pressure on the lower limbs using a wearable sleeve or stocking. Despite the many treatment options available, the market is suffering from a low compliance rate and continues to seek innovative solutions that will reduce patient’s discomfort, decrease hospitalization stay, and improve the patient quality of life.
Venous and lymphatic diseases such as Venous Thromboembolism (VTE), Chronic Venous Insufficiency (CVI), Deep Vein Thrombosis (DVT) and Lymphedema affect a large population worldwide. Age, gender, heredity, pregnancy and lifestyle are conditioning factors. Pain, mobility difficulties, reduced self-esteem, social isolation, disability to work, altered body image and depression affect the quality of life of the elderly and in general of people coping with venous and lymphatic diseases. Yearly, there are approximately 10 million cases of VTE worldwide. VTE-related events kill more people than AIDS, breast cancer, prostate cancer and motor vehicle crashes combined in Europe and U.S. A growing elderly and diabetic population are also key components in the incidence of venous diseases. In addition to disease burden, venous and lymphatic diseases cause significant global economic burden.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › oncology › prostate cancer
• medical and health sciences › clinical medicine › angiology › vascular diseases
• medical and health sciences › health sciences › infectious diseases › RNA viruses › HIV
• medical and health sciences › clinical medicine › oncology › breast cancer
• medical and health sciences › clinical medicine › obstetrics

Programm/Programme

• H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
• H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
• H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Thema/Themen

• SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

ELASTIMED LTD

• Netto-EU-Beitrag: € 50 000,00
• Adresse: HATCHELET 17 ; 2017900 MISGAV IP ; Israel
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Aktivitätstyp
  Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00